Clinical trialNACompleted
Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer
Randomized Phase II Trial of Two Different Nutritional Approaches for Patients Receiving Treatment for Their Advanced Pancreatic Cancer
- Outcome
- Finished, no results posted
- Phase
- NA
- Status
- Completed
- Study type
- Interventional
- Start
- 2 December 2020
- Expected end
- 1 February 2025
- Enrollment
- 32 participants
- Sites
- 6
- Primary outcomes
- Progression-free survival per RECIST 1.1
- Sponsor
- Other
- Results posted
- No
- Last update
- 21 February 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study will evaluate the effects of the ketogenic diet in patients with metastatic pancreatic cancer while receiving chemotherapy.
Detailed description public domain (ClinicalTrials.gov)
A randomized, phase II trial designed to evaluate the progression free survival in patients with metastatic pancreatic cancer on triplet therapy (nab-paclitaxel + gemcitabine + cisplatin) while on ketogenic diet or non-ketogenic diet. This study also aims to compare the changes in serum metabolites and quality of life between the two arms.